Poseida Therapeutics, which launched its IPO on Nasdaq earlier this month, has hired Harry Leonhardt as general counsel and chief compliance officer (CCO).
Leonhardt was most recently senior vice president, general counsel, CCO, corporate secretary and a member of the executive committee at Halozyme Therapeutics. Before working at Halozyme, he was senior vice president for legal and compliance, corporate secretary and a member of the executive committee at Amylin Pharmaceuticals, which was acquired by Bristol Myers Squibb in 2012.
Earlier in his career, Leonhardt served as general counsel for a number of San Diego, California-based biotech companies, and as chief litigation counsel and later as general counsel for the European region at Allergan Pharmaceuticals. Before that he was an intellectual property litigator in Los Angeles.
Poseida Therapeutics is a clinical-stage biopharmaceutical company focused on using proprietary gene-engineering platform technologies to create new cell and gene therapeutics.
‘Harry’s extensive legal expertise and executive management experience in the biopharmaceutical industry make him the ideal person to lead Poseida’s legal and compliance functions as we transition from a private entity to a publicly traded company,’ says company CEO Eric Ostertag in a statement.
‘Moreover, we look forward to the strategic and transactional input Harry will bring as we progress our innovation-based business strategies in the development of differentiated cell and gene therapy product candidates utilizing our core proprietary gene-engineering platform technologies.’
Â
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
